TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8194940

Group type: EXPERIMENTAL
Intervention: Congruence Model intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Self-help groups
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 3792081

Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 15
Study: 31759228

Group type: EXPERIMENTAL
Intervention: Imagery-enhanced interpretation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 0
Study: 28094873

Group type: EXPERIMENTAL
Intervention: Routine day activity program combined with WBV training (WBV at 30 Hz, 2‐mm peak‐to‐peak amplitude) for 9 weeks (18 sessions)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Routine program only without WBV for 9 weeks (18 sessions)
Number of subjects: 54
Study: 28507187

Group type: EXPERIMENTAL
Intervention: Disease activity indices (28‐joint Disease Activity Score, Clinical Disease Activity Index, Simplified Disease Activity Index)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Pain, physician's global assessment (PGA), and patient's global assessment (PtGA) of disease activity
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Composite disease activity indices, patient-reported pain and disease activity, physician-reported disease activity
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Physical function, acute‐phase response, fatigue, participation, emotional well‐being
Number of subjects: 462
Study: 26372507

Group type: EXPERIMENTAL
Intervention: WAVE-covered self-expandable metallic stents (WCS)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Uncovered self-expandable metallic stents (UCS)
Number of subjects: 102
Study: 23421909

Group type: EXPERIMENTAL
Intervention: Implementation of evidence-based infection control practices in ICUs
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Quantitative outcomes on catheter-related bloodstream infections and performance indicators
Number of subjects: 6
Study: 21459363

Group type: EXPERIMENTAL
Intervention: Rapid responders (RR; n = 41)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Non-rapid responders (non-RRs; n = 60)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: DBT-RRs
Number of subjects: 101

Group type: COMPARATOR
Intervention: ACGT-RRs
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Rapid responders (RRs)
Number of subjects: 101
Study: 17999280

Group type: EXPERIMENTAL
Intervention: Intensive intervention (II)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Self-help (SH)
Number of subjects: 71
Study: 15135481

Group type: EXPERIMENTAL
Intervention: Ultrasound scissors (Group A, 45 patients)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No ultrasound scissors (Group B, 47 patients)
Number of subjects: 92
Study: 12233274

Group type: EXPERIMENTAL
Intervention: OP-1 associated with osteosynthesis using a monolateral external fixator
Number of subjects: 0
Study: 9824923

Group type: EXPERIMENTAL
Intervention: MABI and NBAS assessments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no participation in NBAS at delivery, written assessments at home)
Number of subjects: 0
Study: 8133853

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (900 mg/kg for 501-1000 g; 700 mg/kg for 1001-1500 g), repeated every 14 days until certain criteria were met
Number of subjects: 2416

Group type: COMPARATOR
Intervention: Control (placebo infusions during phase 1, none during phase 2)
Number of subjects: 2416

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin
Number of subjects: 2416

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2416
Study: 2683557

Group type: EXPERIMENTAL
Intervention: Nimodipine (40 mg t.i.d. for 28 days)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (identical tablets)
Number of subjects: 41
Study: 31022099

Group type: EXPERIMENTAL
Intervention: Health coaching and monetary incentives (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No health coaching and monetary incentives (Group B)
Number of subjects: 0
Study: 29540864

Group type: EXPERIMENTAL
Intervention: Extended-release guanfacine (GEXR)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 26778524

Group type: EXPERIMENTAL
Intervention: Atorvastatin 60 mg (AT 60)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg (AT 20)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups (AT 60 mg and AT 20 mg)
Number of subjects: 46
Study: 24643313

Group type: EXPERIMENTAL
Intervention: Family intervention delivered at individual, family, and community levels.
Number of subjects: 79
Study: 23158914

Group type: EXPERIMENTAL
Intervention: Serum total bilirubin (TBil) levels stratified into three groups: lower-level group (TBil ≤ 12.8 mmol/L), moderate-level group (TBil > 12.8 ∼ 18.2 mmol/L), higher-level group (TBil > 18.2 mmol/L)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Serum total bilirubin (TBil) levels
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Pulse pressure measurements
Number of subjects: 140
Study: 19657349

Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 18594091

Group type: EXPERIMENTAL
Intervention: Combined popliteal and ankle block
Number of subjects: 63

Group type: COMPARATOR
Intervention: Ankle block alone
Number of subjects: 63
Study: 16205916

Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg t.i.d.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Alprazolam (1 mg t.i.d.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12956257

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% once daily
Number of subjects: 1381

Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 1381

Group type: COMPARATOR
Intervention: Latanoprost 0.005% once daily
Number of subjects: 1381
Study: 10629018

Group type: EXPERIMENTAL
Intervention: Itraconazole cyclodextrin solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Itraconazole capsules
Number of subjects: 40
Study: 8656304

Group type: EXPERIMENTAL
Intervention: 1-day fetal monitoring workshop and a review session 6 months later
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 109
Study: 1347039

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6395273

Group type: EXPERIMENTAL
Intervention: Cefonicid (1.0 g every 24 hr)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Cefamandole (1.0 g iv every 6 hr)
Number of subjects: 147
Study: 31034102

Group type: EXPERIMENTAL
Intervention: High expectations of improvement
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: High expectations of improvement (controlling for potential confounders)
Number of subjects: 593

Group type: COMPARATOR
Intervention: Baseline pain intensity, psychological profile, and self-rated health
Number of subjects: 593
Study: 30128710

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (n=284)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Aspirin alone (n=286)
Number of subjects: 570
Study: 26615509

Group type: EXPERIMENTAL
Intervention: 15 mg of meloxicam
Number of subjects: 36

Group type: COMPARATOR
Intervention: 100 mg of diclofenac
Number of subjects: 36
Study: 24216088

Group type: EXPERIMENTAL
Intervention: L-dopa with benserazide
Number of subjects: 33
Study: 22348456

Group type: EXPERIMENTAL
Intervention: Plant-extractive compound
Number of subjects: 0
Study: 20662070

Group type: EXPERIMENTAL
Intervention: AZD5672 (20, 50, 100, or 150 mg orally, once daily)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg subcutaneously, once weekly)
Number of subjects: 371
Study: 17931467

Group type: EXPERIMENTAL
Intervention: Unitary estimates of personal risk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bounded estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial unitary estimates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estimates regarding the average student
Number of subjects: 0
Study: 15770222

Group type: EXPERIMENTAL
Intervention: Oligofructose (OFS) 16 g/day for 8 weeks
Number of subjects: 7

Group type: COMPARATOR
Intervention: Maltodextrine (placebo)
Number of subjects: 7
Study: 12075945

Group type: EXPERIMENTAL
Intervention: EBP Pak
Number of subjects: 327

Group type: COMPARATOR
Intervention: VC Pak
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: EBP Jar
Number of subjects: 327

Group type: COMPARATOR
Intervention: VC Jar
Number of subjects: 327
Study: 10395619

Group type: EXPERIMENTAL
Intervention: Oligofructose (Raftilose P95) 2 g three times daily for 4 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sucrose 1 g three times daily for 4 weeks (Control)
Number of subjects: 21
Study: 7671182

Group type: EXPERIMENTAL
Intervention: Diltiazem (calcium blocker)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No calcium blocker (control)
Number of subjects: 0
Study: 2019378

Group type: EXPERIMENTAL
Intervention: 5 days of single-agent cefotaxime, 2 g IV every 8 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: 10 days of single-agent cefotaxime, 2 g IV every 8 hours
Number of subjects: 100
Study: 7082501

Group type: EXPERIMENTAL
Intervention: Histamine infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Nitroprusside infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Histamine infusion with cimetidine
Number of subjects: 6
Study: 30482602

Group type: EXPERIMENTAL
Intervention: Stabilization exercises plus neuromuscular electrical stimulation (n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stabilization exercises only (n=15)
Number of subjects: 30
Study: 30106876

Group type: EXPERIMENTAL
Intervention: Clozapine treatment with a 1-kg gain in body weight
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Clozapine treatment with a 1-point increase in percentage of body fat
Number of subjects: 47
Study: 26246430

Group type: EXPERIMENTAL
Intervention: AZD7009
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 23343614

Group type: EXPERIMENTAL
Intervention: Doxazosin 0.03 mg/kg/d once daily before bed (group 2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ibuprofen 20 mg/kg/d divided into 2 doses for pain control (group 1)
Number of subjects: 45
Study: 21832031

Group type: EXPERIMENTAL
Intervention: Random schedule of grip force pattern training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blocked schedule of grip force pattern training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blocked schedule of grip force pattern training with poor visuospatial working memory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random schedule of grip force pattern training in individuals poststroke
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blocked schedule of grip force pattern training in individuals poststroke
Number of subjects: 0
Study: 18313350

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (EPO)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 76
Study: 16492072

Group type: EXPERIMENTAL
Intervention: Indapamide slow-release +/- Perindopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12707576

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 0
Study: 10990013

Group type: EXPERIMENTAL
Intervention: Standard setting according to the manufacturer's software
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Reduced gain and maximum output
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both settings (standard and reduced)
Number of subjects: 20
Study: 9166205

Group type: EXPERIMENTAL
Intervention: Endometrial Laser Ablation (ELA)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Transcervical Resection of the Endometrium (TCRE)
Number of subjects: 372
Study: 1603535

Group type: EXPERIMENTAL
Intervention: Subconjunctival 5-fluorouracil (5-FU) injections, 4 to 6 injections over 10 days postoperatively.
Number of subjects: 41

Group type: COMPARATOR
Intervention: No treatment with 5-fluorouracil (5-FU).
Number of subjects: 41
Study: 3954937

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Zolpidem 30 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 2
Study: 29793446

Group type: EXPERIMENTAL
Intervention: Propranolol administration
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study: 27546095

Group type: EXPERIMENTAL
Intervention: EMD
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bio-Oss Collagen
Number of subjects: 24
Study: 24237113

Group type: EXPERIMENTAL
Intervention: Brief Symptom Inventory (BSI) administered at 30, 90, and 180 days postinjury
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Gender and race/ethnicity as factors in improvement rates
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Predictors of clinically significant GSI elevations
Number of subjects: 872
Study: 23009189

Group type: EXPERIMENTAL
Intervention: Multi-modal exercise program (twice weekly, 60 minute classes for 16 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-exercise control group
Number of subjects: 0
Study: 20102345

Group type: EXPERIMENTAL
Intervention: Alcoholics Anonymous (AA) attendance
Number of subjects: 1706
Study: 18319361

Group type: EXPERIMENTAL
Intervention: second-generation electrically heated cigarette smoking system (EHCSS)
Number of subjects: 97

Group type: COMPARATOR
Intervention: conventional cigarettes
Number of subjects: 97
Study: 18986412

Group type: EXPERIMENTAL
Intervention: Nesiritide administration
Number of subjects: 25
Study: 15121562

Group type: EXPERIMENTAL
Intervention: Soy-based food supplement (n = 9) for 5 consecutive evenings
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo tablet (n = 19) for 5 consecutive evenings
Number of subjects: 28
Study: 11509866

Group type: EXPERIMENTAL
Intervention: s.c. GH 0.1 IU/kg/day
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: co-administration of GH and prednisolone
Number of subjects: 8

Group type: COMPARATOR
Intervention: oral prednisolone 50 mg/day
Number of subjects: 8
Study: 9380239

Group type: EXPERIMENTAL
Intervention: Vitamin-E-modified cellulose (CL-E) dialysis membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional dialysis membranes
Number of subjects: 0
Study: 8423488

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Trunk elevation with knee flexion position
Number of subjects: 192

Group type: COMPARATOR
Intervention: Trunk elevation
Number of subjects: 192

Group type: COMPARATOR
Intervention: Knee flexion
Number of subjects: 192
Study: 2824861

Group type: EXPERIMENTAL
Intervention: Adjuvant medroxyprogesterone acetate (500 mg, 3 times a week for 1 year)
Number of subjects: 136

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 136
Study: 31541424

Group type: EXPERIMENTAL
Intervention: Lacrosse non-slip elements (NSE)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Cutting balloons
Number of subjects: 79
Study: 30138013

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Sertraline (SRT)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: CBT or COMB treatment
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Treatment remission
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Treatment responders and remitters
Number of subjects: 319
Study: 26349936

Group type: EXPERIMENTAL
Intervention: High NaCl diet (32 g/d) supplemented with 90 mmol KHCO3/day for 10 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High NaCl diet (31 g/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low NaCl diet (3 g/day) with acidified diet
Number of subjects: 8
Study: 25702372

Group type: EXPERIMENTAL
Intervention: Occupational Performance Coaching for stroke survivors (OPC‐Stroke), 10 sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 22782948

Group type: EXPERIMENTAL
Intervention: pegIFN-α2a/ribavirin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL28B genotype
Number of subjects: 0
Study: 20966595

Group type: EXPERIMENTAL
Intervention: Complex plaque detected in patients assessed by 3DTEE
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Presence of complex plaque
Number of subjects: 350
Study: 17924894

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (up to 1 microg x kg(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam (up to 5 mg)
Number of subjects: 60
Study: 15717206

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (sIMV)
Number of subjects: 40
Study: 12419095

Group type: EXPERIMENTAL
Intervention: Ofloxacin 0.3%
Number of subjects: 48

Group type: COMPARATOR
Intervention: Trimethoprim sulfate 0.1%/polymyxin B
Number of subjects: 48
Study: 9450712

Group type: EXPERIMENTAL
Intervention: Paroxetine, 20 to 30 mg/d
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nortriptyline, targeted to a therapeutic plasma level of 190 to 570 nmol/L (50‐150 ng/mL)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 81
Study: 7649899

Group type: EXPERIMENTAL
Intervention: Cortisol responses to exercise measured relative to circadian baselines
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cortisol responses to exercise measured relative to preexercise concentrations
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cortisol responses calculated relative to circadian baselines
Number of subjects: 8
Study: 2628631

Group type: EXPERIMENTAL
Intervention: Task-relevant content
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mood works
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive thinking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal thinking (control)
Number of subjects: 0
Study: 1181365

Group type: EXPERIMENTAL
Intervention: Group discussion program
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Individual briefing program
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 31628978

Group type: EXPERIMENTAL
Intervention: 5-ASA colon delivery system
Number of subjects: 0
Study: 28673808

Group type: EXPERIMENTAL
Intervention: LARGE portion size (200% of SMALL, 2166 kcal)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SMALL portion size (1083 kcal)
Number of subjects: 20

Group type: COMPARATOR
Intervention: NO TV
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TV
Number of subjects: 20
Study: 25713485

Group type: EXPERIMENTAL
Intervention: Amoxicillin plus metronidazole in combination with scaling and root planning (SRP)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Scaling and root planning (SRP) alone (control)
Number of subjects: 28
Study: 23410871

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg before emergency PCI, followed by atorvastatin 40 mg for 4 weeks and atorvastatin 20 mg for 20 weeks (Group A)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg for 4 weeks and atorvastatin 20 mg for 20 weeks without pre-PCI loading dose (Group B)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg for 24 weeks only post-PCI (Group C)
Number of subjects: 102
Study: 21639907

Group type: EXPERIMENTAL
Intervention: Infliximab alone (5 mg/kg at weeks 0, 2, 6, 12, and 18)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Infliximab combined with Methotrexate (10 mg/week)
Number of subjects: 26
Study: 19938941

Group type: EXPERIMENTAL
Intervention: Brief iterative consultation
Number of subjects: 346

Group type: COMPARATOR
Intervention: Control brochure
Number of subjects: 346
Study: 17584550

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study: 15509358

Group type: EXPERIMENTAL
Intervention: Positively framed strong messages advocating exercise from a credible source
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Positively framed strong messages advocating exercise from a non-credible source
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Negatively framed strong messages advocating exercise from a credible source
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Negatively framed strong messages advocating exercise from a non-credible source
Number of subjects: 450

Group type: COMPARATOR
Intervention: No-source control condition
Number of subjects: 450
Study: 16422973

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vardenafil 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vardenafil (all doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11762729

Group type: COMPARATOR
Intervention: No glove
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Leather glove
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nitrile glove
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Vinyl glove
Number of subjects: 41
Study: 9414376

Group type: COMPARATOR
Intervention: Seated on a chair designed to alleviate workload
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Kneeling posture
Number of subjects: 10
Study: 8099640

Group type: EXPERIMENTAL
Intervention: Evening primrose oil
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Evening primrose oil and fish oil
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 3429863

Group type: EXPERIMENTAL
Intervention: Nicardipine 50 mg twice daily for 3 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40